For the quantification of PD-L1 expression (biomarker in cancer immunotherapy), CCL18, TNFAIP6, and BCL2A1 had higher diagnostic efficiency (AUC > 0.7) (Figure 5D). The gene discussed is CCL18; the disease is cancer.